Heavy LIFting: tumor promotion and radioresistance in NPC.
Level V
Where this comes from
- Record sourced from PubMed, PMID 24270417.
- Also identified by DOI 10.1172/JCI73416 and PMC identifier 3859398.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The epithelial-derived nasopharyngeal carcinoma (NPC) is a rare tumor in most of the world; however, it is common in southern China, northern Africa, and Alaska. NPC is often left undiagnosed and untreated until a late stage of disease. Furthermore, while radiation therapy is effective against this tumor, local recurrence due to radioresistance is an important clinical problem. In this issue, Liu et al. report on their identification of the IL-6 family cytokine leukemia inhibitory factor (LIF) as a serum predictor of local NPC recurrence following radiation therapy. The authors developed this initial finding to discover a role for the LIF/LIFR/mTORC1 signaling axis in NPC tumor cell growth as well as radioresistance.
Medical subject headings
- Carcinoma
- Leukemia Inhibitory Factor
- Nasopharyngeal Neoplasms
- Neoplasm Proteins